...
首页> 外文期刊>Cancer Cell >Targeting Non-proteolytic Protein Ubiquitination for the Treatment of Diffuse Large B Cell Lymphoma
【24h】

Targeting Non-proteolytic Protein Ubiquitination for the Treatment of Diffuse Large B Cell Lymphoma

机译:靶向非蛋白水解蛋白泛素化治疗弥漫性大B细胞淋巴瘤

获取原文
获取原文并翻译 | 示例
           

摘要

Chronic active B cell receptor (BCR) signaling, a hallmark of the activated B cell-like (ABC) subtype of diffuse large B cell lymphoma (DLBCL), engages the CARD11-MALT1-BCL10 (CBM) adapter complex to activate I kappa B kinase (IKK) and the classical NF-kappa B pathway. Here we show that the CBM complex includes the E3 ubiquitin ligases cIAP1 and cIAP2, which are essential mediators of BCR-dependent NF-kappa B activity in ABC DLBCL. cIAP1/2 attach K63-linked polyubiquitin chains on themselves and on BCL10, resulting in the recruitment of IKK and the linear ubiquitin chain ligase LUBAC, which is essential for IKK activation. SMAC mimetics target cIAP1/2 for destruction, and consequently suppress NF-kB and selectively kill BCR-dependent ABC DLBCL lines, supporting their clinical evaluation in patients with ABC DLBCL.
机译:慢性活动性B细胞受体(BCR)信号是弥漫性大B细胞淋巴瘤(DLBCL)的激活B细胞样(ABC)亚型的标志,它与CARD11-MALT1-BCL10(CBM)衔接子复合体结合以激活IκB激酶(IKK)和经典的NF-κB途径。在这里,我们显示CBM复合物包括E3泛素连接酶cIAP1和cIAP2,它们是ABC DLBCL中依赖BCR的NF-κB活性的重要介体。 cIAP1 / 2在其自身和BCL10上连接K63连接的聚泛素链,从而导致IKK和线性泛素链连接酶LUBAC募集,这对于IKK激活至关重要。 SMAC模拟物靶向cIAP1 / 2进行破坏,从而抑制NF-kB并选择性杀死依赖BCR的ABC DLBCL系,从而支持其对ABC DLBCL患者的临床评估。

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号